Literature DB >> 16820299

Delineating common molecular mechanisms in Alzheimer's and prion diseases.

Kevin J Barnham1, Roberto Cappai, Konrad Beyreuther, Colin L Masters, Andrew F Hill.   

Abstract

The structure of the infectious agent responsible for prion diseases has not been fully characterized, but evidence points to a beta-rich conformer of the host-encoded prion protein. Amyloid-beta peptide (Abeta), a proteolytic fragment generated from the amyloid precursor protein, has been implicated as the toxic molecule involved in the pathogenesis of Alzheimer's disease. The mechanism of Abeta toxicity might be mediated through the coordination of redox-active transition-metal ions such as copper leading to the generation of reactive oxygen species, coupled with the propensity to interact with lipid bilayers. Key sequence and chemical similarities between prion protein (PrP) and Abeta indicate that similar therapeutic strategies might be applicable for the treatment of Alzheimer's and prion diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820299     DOI: 10.1016/j.tibs.2006.06.006

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  30 in total

Review 1.  Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders.

Authors:  Silvio R Bareggi; Umberto Cornelli
Journal:  CNS Neurosci Ther       Date:  2010-12-27       Impact factor: 5.243

Review 2.  How is protein aggregation in amyloidogenic diseases modulated by biological membranes?

Authors:  Christopher Aisenbrey; Tomasz Borowik; Roberth Byström; Marcus Bokvist; Fredrick Lindström; Hanna Misiak; Marc-Antoine Sani; Gerhard Gröbner
Journal:  Eur Biophys J       Date:  2007-11-21       Impact factor: 1.733

3.  Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies.

Authors:  Joao P Lopes; Catarina R Oliveira; Paula Agostinho
Journal:  Cell Mol Neurobiol       Date:  2007-10-27       Impact factor: 5.046

Review 4.  Redox control of prion and disease pathogenesis.

Authors:  Neena Singh; Ajay Singh; Dola Das; Maradumane L Mohan
Journal:  Antioxid Redox Signal       Date:  2010-06-01       Impact factor: 8.401

5.  Genetic variability of the gene cluster CALHM 1-3 in sporadic Creutzfeldt-Jakob disease.

Authors:  Olga Calero; María J Bullido; Jordi Clarimón; Rafael Hortigüela; Ana Frank-García; Pablo Martínez-Martín; Alberto Lleó; María Jesús Rey; Isabel Sastre; Alberto Rábano; Jesús de Pedro-Cuesta; Isidro Ferrer; Miguel Calero
Journal:  Prion       Date:  2012-08-09       Impact factor: 3.931

6.  Do prion protein gene polymorphisms induce apoptosis in non-mammals?

Authors:  Tuğçe Birkan; Mesut Şahin; Zubeyde Öztel; Erdal Balcan
Journal:  J Biosci       Date:  2016-03       Impact factor: 1.826

7.  Conservation of a glycine-rich region in the prion protein is required for uptake of prion infectivity.

Authors:  Christopher F Harrison; Victoria A Lawson; Bradley M Coleman; Yong-Sun Kim; Colin L Masters; Roberto Cappai; Kevin J Barnham; Andrew F Hill
Journal:  J Biol Chem       Date:  2010-03-31       Impact factor: 5.157

8.  The effect of ferulic acid against lead-induced oxidative stress and DNA damage in kidney and testes of rats.

Authors:  Eman G Kelainy; Ibrahim M Ibrahim Laila; Shaimaa R Ibrahim
Journal:  Environ Sci Pollut Res Int       Date:  2019-09-04       Impact factor: 4.223

9.  Proteomic Analyses for the Global S-Nitrosylated Proteins in the Brain Tissues of Different Human Prion Diseases.

Authors:  Li-Na Chen; Qi Shi; Bao-Yun Zhang; Xiao-Mei Zhang; Jing Wang; Kang Xiao; Yan Lv; Jing Sun; Xiao-Dong Yang; Cao Chen; Wei Zhou; Jun Han; Xiao-Ping Dong
Journal:  Mol Neurobiol       Date:  2015-09-21       Impact factor: 5.590

10.  Helices 2 and 3 are the initiation sites in the PrP(C) → PrP(SC) transition.

Authors:  Jie Chen; D Thirumalai
Journal:  Biochemistry       Date:  2012-12-31       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.